Search clinical trials for: TAK-418 Matching Placebo

Total 1941 results

Millennium Pharmaceuticals, Inc.

Terminated

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single and Multiple Oral Dose of TAK-418 in Healthy Female Participants

Healthy Volunteers

United States
Takeda

Completed

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Ascending Oral Single Dose of TAK-418 in Healthy Participants

Healthy Participants

United States
Takeda

Withdrawn

A Study to Evaluate the Safety, Pharmacokinetics (PK), and Efficacy of TAK-671 for the Treatment of Coronavirus Disease (COVID) 2019 in Adults

Coronavirus Disease
Takeda

Completed

TAK-438 - Safety, Blood Levels & Effects of Repeated Doses (TAK-438_107)

Gastroesophageal Reflux Disease (GERD) | Erosive Esophagitis(EE)

United Kingdom
Samsung Bioepis Co., Ltd.

Completed

A Phase I Study of SB26 in Healthy Volunteers

Healthy Volunteers

United States
Takeda

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-438 in Healthy Male Participants

Dose Finding Study
Takeda
Takeda Development Center Americas, Inc.

Terminated

A Study of TAK-018 in Preventing the Recurrence of Crohn's Disease After Surgery

Crohn Disease

United States, Germany, Austria, France, United Kingdom
Neurocrine Biosciences
Takeda

Completed

A Study to Evaluate Multiple Oral Doses of Luvadaxistat in Adults With Schizophrenia

Schizophrenia

United States
Takeda

Completed

Safety, Tolerability and Pharmacokinetics of TAK-438 in Healthy Male Participants

Ascending Single Dose Study
Takeda

Completed

Efficacy of TAK-438 Compared to Placebo in the Treatment of Non-Erosive Gastroesophageal Reflux Disease

Non-erosive Gastroesophageal Reflux Disease

Japan
Takeda

Terminated

Effects of TAK-448 in Middle-aged and Older Men With Low Testosterone

Low Testosterone

United States
Takeda

Completed

A Bioequivalence (BE) Study of TAK-438 Orally Disintegrating (OD) Tablet

Japanese Healthy Adult Male

Japan
Takeda

Completed

Phase 3 Study of TAK-438 10 mg in the Treatment of Non-Erosive Gastroesophageal Reflux Disease (NERD)

Non-erosive Gastroesophageal Reflux Disease

Japan
Kangpu Biopharmaceuticals, Ltd.

Completed

Safety, Tolerability and Pharmacokinetics of KPG-818 in Healthy Subjects

Systemic Lupus Erythematosus

United States
Takeda

Completed

Long-Term Safety Study of TAK-438 in the Maintenance Treatment of Healed Erosive Esophagitis

Erosive Esophagitis

Japan
Takeda

Completed

A Pharmacokinetic Study of TAK-438 in Healthy Adult Chinese Participants

Healthy Participants

China
Avid Radiopharmaceuticals

Terminated

A Phase 0, Open Label, Multi-Center, Exploratory and Safety Study of [F-18]T808 (T808)

Alzheimers Disease

United States
Avid Radiopharmaceuticals

Terminated

A Phase 0, Open Label, Multi-center Exploratory and Safety Study of [F-18]T807

Alzheimers Disease | AD

United States
Takeda

Completed

Special Drug Use Surveillance of Vonoprazan for "Maintenance Therapy of Reflux Esophagitis: Long-term Use"

Reflux Esophagitis

Japan
Takeda

Completed

Drug Use Surveillance of Vonoprazan for "Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis"

Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis

Japan
Sage Therapeutics

Active, not recruiting

A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)

Mild Cognitive Impairment | Alzheimer's Disease | Mild Dementia

United States, Puerto Rico
Sage Therapeutics

Completed

A Study to Evaluate the Effects of SAGE-718 in Participants With Parkinson's Disease Cognitive Impairment

Parkinson Disease | Cognitive Dysfunction

United States
Takeda
Richmond Pharmacology Limited

Completed

Safety, Tolerability, and Pharmacokinetics of TAK-438 in Healthy Western Male Subjects, Preliminary Food Effect Analysis, and an Ethnic Comparison With Japanese Subjects

Dose Finding Study
Takeda

Terminated

A Study With [18F]MNI-1054 to Determine Lysine -Specific Demethylase 1A (LSD1) Brain Enzyme Occupancy of TAK-418 After Single-Dose Oral Administration in Healthy Participants

Healthy Volunteers

United States
Takeda

Completed

A Randomized, Double-Blind, Multicenter Study to Evaluate the Acid-inhibitory and Dose-response Efficacy of TAK-438 (20 mg, 40 mg) in Patients With Proton Pump Inhibitor (PPI) - Resistant Erosive Esophagitis

Erosive Esophagitis

Japan
Takeda

Completed

Single-Dose Phase 1 Study of TAK-792

Healthy Male Adults Participants

Japan
Takeda

Withdrawn

A Phase 1, Single and Multiple Dose Study of TAK-137

Healthy Japanese Adult Male

Japan
Nowarta Biopharma Inc

Completed

A Phase I/II Double-blind Safety and Efficacy Evaluation of Nowarta110 in Patients With Plantar Warts

Plantar Warts

United States
Takeda

Completed

A Study of TAK-951 in Healthy Adults

Healthy Volunteers

United States
Takeda

Completed

A Study of TAK-951 in Healthy Adults

Healthy Volunteer

United States
Takeda

Terminated

Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of TAK-137 in Adults With Attention-Deficit/Hyperactivity Disorder.

Attention-Deficit/Hyperactivity Disorder

United States
Takeda

Terminated

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Cardiovascular Disease | Type 2 Diabetes

United States, France, Poland, Ukraine, Germany, Hong Kong, Taiwan, Argentina, Israel, Mexico, Bulgaria, Malaysia, Romania, Canada, Korea, Republic of, New Zealand, Peru, Estonia, Philippines, Russian Federation, Czech Republic, H... and more
Millennium Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-079 in Combination With Standard Background Therapy in Participants With Moderate to Severe Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus | Lupus Erythematosus, Systemic

United States
Takeda
Takeda Development Center Americas, Inc.

Completed

A Study of TAK-954 to Treat Gastrointestinal Dysfunction in Adults After Surgery

Postoperative Gastrointestinal Dysfunction

United States, Germany
Neurocrine Biosciences
Takeda

Completed

Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study

Schizophrenia | Healthy Volunteers

United States
Neurocrine Biosciences
Takeda

Completed

TAK-653 Escalating Single and Multiple Dose Study in Healthy Participants

Depressive Disorder

United Kingdom
Millennium Pharmaceuticals, Inc.

Completed

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of TAK-954 in Healthy Adult Participants

Healthy Volunteers

United States
Takeda

Completed

Safety, Tolerability and Pharmacokinetic Study of Multiple Rising Doses of TAK- 063 in Participants With Stable Schizophrenia and Healthy Participants

Schizophrenia

United States
Takeda

Terminated

Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 and 50mg in Asia Pacific Adults With Type 2 Diabetes (GRAND-307)

Type 2 Diabetes Mellitus

Taiwan, China, Korea, Republic of, New Zealand, Australia
Millennium Pharmaceuticals, Inc.

Completed

A Study of a Single Intravenous Infusion Dose of TAK-925 in Participants With Idiopathic Hypersomnia

Idiopathic Hypersomnia

United States, Japan
Takeda

Withdrawn

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-988 in Healthy Participants

Healthy Volunteers

United States
Neurocrine Biosciences
Takeda

Completed

Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adults With Friedreich Ataxia

Friedreich Ataxia

United States
Takeda

Completed

Phase 1 TAK-906 Single and Multiple Ascending Dose Study in Japanese Healthy Male Participants

Japanese Healthy Adult Male Participants

Japan
Takeda

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Healthy Participants

Healthy Participants

United States
Neurocrine Biosciences
Takeda

Terminated

A TAK-831-1001, Single and Multiple Rising Dose Study in Healthy Participants

Schizophrenia, Cerebellar Ataxia

United Kingdom
Takeda

Completed

A Study of TAK-079 in People With Generalized Myasthenia Gravis

Myasthenia Gravis

United States, Spain, Canada, Serbia, Italy, Poland
Takeda

Terminated

A Phase 2a Pharmacodynamic Study of TAK-448 in Participants With Hypogonadotropic Hypogonadism

Hypogonadotropic Hypogonadism

United Kingdom
Takeda

Completed

A Study of TAK-105 in Healthy Adults

Healthy Volunteers

United States
Eastern Virginia Medical School
Emory University; Centers for Disease Control and Prevention; CONRAD

Recruiting

Rectal Insert TAF/EVG Pre-Exposure Prophylaxis (RITE PrEP) Study (RITE PrEP)

Safety Issues

United States
Takeda

Completed

A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Non-Steroid Anti-Inflammatory Drug (NSAID) Therapy

Gastric Ulcer | Duodenal Ulcer

Japan

3

Subscribe